Franc Benjamin L, Mari Carina, Johnson Denise, Leong Stanley P
Department of Radiology, University of California San Francisco, San Francisco, CA 94143-0252, USA.
Clin Nucl Med. 2005 Dec;30(12):787-91. doi: 10.1097/01.rlu.0000186856.86505.96.
This preliminary study retrospectively evaluated the ability of intraoperative localization of recurrent melanoma using F-18 fluorodeoxyglucose (FDG) and a probe sensitive to both high-energy gamma rays and positrons to enable complete tumor resection and improved patient outcome.
Three hours before surgery for resection of recurrent melanoma, 5 patients (mean age, 52 +/- 22 years) with a history of local surgery, radiation therapy, and/or large habitus received 14.6 +/- 3.2 mCi of F-18 FDG. Intraoperative tumor localization was performed with a radiation probe (PET-Probe; IntraMedical Imaging LLC, Los Angeles, CA). Intraoperative tumor tissue activities, background tissue activities, pathology results, and patient follow up (clinical/imaging) were recorded.
Eight of the 19 surgical specimens were identified by the probe as having increased FDG uptake when compared with the surrounding tissues before resection. All 8 specimens contained melanoma. Of the 11 specimens that were not identified using the probe, one contained melanoma, yielding a sensitivity of 89% (8 of 9) and a specificity of 100% (10 of 10). In 3 of the 5 cases, the probe allowed the identification of nonvisualized and nonpalpable tumor foci that were later confirmed pathologic. At an average follow up of 210 days (range, 30-515 days), 2 of 5 patients had no evidence of recurrent melanoma by clinical or radiographic evaluations.
In the setting of recurrent melanoma, there appear to be potential benefits to intraoperative detection with FDG and a positron-detecting probe, particularly in cases with challenging or altered anatomy.
本初步研究回顾性评估了使用F-18氟脱氧葡萄糖(FDG)和一种对高能伽马射线和正电子均敏感的探头对复发性黑色素瘤进行术中定位,以实现肿瘤完全切除并改善患者预后的能力。
在复发性黑色素瘤切除术前3小时,5例(平均年龄52±22岁)有局部手术、放射治疗和/或体型较大病史的患者接受了14.6±3.2mCi的F-18 FDG。术中使用放射探头(PET-Probe;IntraMedical Imaging LLC,洛杉矶,加利福尼亚州)进行肿瘤定位。记录术中肿瘤组织活性、背景组织活性、病理结果以及患者随访情况(临床/影像学)。
与切除前周围组织相比,19个手术标本中有8个被探头识别为FDG摄取增加。所有8个标本均含有黑色素瘤。在未使用探头识别的11个标本中,1个含有黑色素瘤,灵敏度为89%(9个中的8个),特异性为100%(10个中的10个)。在5例中的3例中,探头能够识别出后来经病理证实的不可见且不可触及的肿瘤病灶。平均随访210天(范围30 - 515天),5例患者中有2例经临床或影像学评估无复发性黑色素瘤的证据。
在复发性黑色素瘤的情况下,使用FDG和正电子检测探头进行术中检测似乎有潜在益处,特别是在解剖结构具有挑战性或发生改变的病例中。